Kontafarma China Holdings (HKG:1312) expects a consolidated net loss between HK$79.2 million and HK$118.8 million in 2024, wider than the HK$61.1 million net loss in 2023, a Tuesday Hong Kong bourse filing said.
The pharmaceutical company attributed the anticipated increase to an impairment recognized on intangible assets associated with its fitness business, as well as the absence of a one-time gain from the disposal of subsidiaries, which had been recorded during the same period last year.
Shares of the company were down nearly 7% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.